Immuron Ltd

Immuron Ltd Annual Investment Review (2024)

---

1. What does Immuron do?

Immuron develops gut health treatments like their flagship product ProIBS®. While the annual report didn’t share major updates about their day-to-day operations, regulatory progress and ProIBS® remain central to their story.

---

2. Money talk: Key financial updates

The good news:

• Smaller losses: Net loss dropped to $1.15 million (from $4.8 million last year) thanks to better cost control
• R&D focus: Spent $985k researching gut health solutions
• Conflict-free spending: Saved $102k/year by ending deals with companies tied to former executives

What changed:

• Executive pay overhaul: Leaders now get 85-100% of their pay as fixed salary (down from bonus-heavy packages). For example, the CEO’s cash bonus dropped from 15% to 0% of total pay.
• Stock rewards surge: Executives received 6.43 million stock options this year alone – more than five times the total granted from 2021-2023. The R&D head alone holds 1.43M options.

---

3. Wins vs. challenges

Progress:

• Cleaner governance with no insider deals
• Saved $12,896 by adjusting old executive stock grants

Concerns:

• Leadership shakeup: Two directors resigned in May/June 2024 during new appointee Joughin’s onboarding
• Stock option volatility: Some expired unused (e.g., 1.6M options lapsed for Daniel Pollock) while new grants skyrocketed

---

4. What’s next?

• ProIBS® push: 1 million stock options granted to new leadership signal confidence in upcoming launches
• Paycheck stability: Shift to fixed salaries (vs bonuses) aims to retain talent during product development

---

5. Risks to consider

• Your shares could shrink: If executives exercise all 6.43M+ new stock options, existing investors’ ownership stakes will dilute significantly
• Leadership gaps: Two sudden director exits create uncertainty – new appointee Joughin needs to deliver results

---

The bottom line for investors:
Immuron’s cutting costs and aligning leadership with shareholders through stock incentives, but there’s a catch. While smaller losses and focused R&D are positive signs, the massive stock option grants could dramatically dilute your investment if ProIBS® doesn’t succeed. The company appears stable enough for cautious investors comfortable with biotech risks, but watch closely for:

1. Progress on ProIBS® launches
2. Whether leadership stabilizes
3. How many stock options actually get exercised

Transparency note: Immuron’s annual report lacked detailed operational updates, which may require investors to dig deeper before deciding.